A Phase 1, Single-Dose, Open-Label, Randomized Cross-Over Study Evaluating the Bioavailability and Food Effect of Veliparib Tablets Followed by an Extension in Subjects With Ovarian Cancer
Not yet recruiting
Phase of Trial: Phase I
Latest Information Update: 18 Jun 2018
At a glance
- Drugs Veliparib (Primary) ; Carboplatin; Paclitaxel
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Pharmacokinetics
- Sponsors AbbVie
- 12 Jun 2018 Planned End Date changed from 12 Apr 2020 to 24 May 2022.
- 12 Jun 2018 Planned primary completion date changed from 25 Feb 2019 to 13 Mar 2021.
- 12 Jun 2018 Planned initiation date changed from 30 Mar 2018 to 31 May 2020.